Results of a phase II study with sunitinilb malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs)

被引：0
|
作者：
Kulka, M.
Lenz, H.
Meropol, N.
Posey, J.
Picus, J.
Ryan, D.
Bergsland, E.
Stuart, K.
Baum, C.
Fuchs, C.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Calif Los Angeles, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Univ Alabama, Birmingham, AL USA
[5] Washington Univ, St Louis, France
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[8] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[9] Pfizer Inc, La Jolla, CA USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [1] A phase 2 study to evaluate the efficacy and safety of SU 11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)
    Kulke, M
    Lenz, HJ
    Meropol, NJ
    Posey, J
    Ryan, DP
    Picus, J
    Bergsland, E
    Stuart, K
    Baum, CM
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 310S - 310S
  • [2] SU11248 (sunitinib malate) therapy in patients with refractory metastatic breast cancer: preliminary safety and efficacy results from a phase II study
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 172 - 172
  • [3] Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC)
    Escudier, Bernard
    Roigas, Jan
    Gillessen, Silke
    Srinivas, Sandhya
    Pisa, Pavel
    Vogelzang, Nicholas
    Fountzilas, George
    Peschel, Christian
    Baum, Charles M.
    De Mulder, Pieter
    ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [4] Modulation of biomarkers of angiogenesis during treatment with SU11248 (sunitinib malate) in patients with advanced malignancies
    Deprimo, Samuel E.
    Toner, Guy
    Mitchell, Paul
    De Boer, Richard
    Gibbs, Peter
    Hicks, Rodney
    McArthur, Grant
    Brega, Nicoletta
    McCarthy, Timothy
    Bello, Carlo
    CANCER RESEARCH, 2006, 66 (08)
  • [5] A phase II study of pemetrexed in patients (pts) with advanced neuroendocrine tumors (NETs)
    Bhargava, P.
    Earle, C. C.
    Zhu, A. X.
    Clark, J. W.
    Vincitore, M.
    Battu, S.
    Regan, E.
    Lawrence, C.
    Kulke, M. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Phase II study of SU11248 inpatients with advanced malignancies incorporating PET imaging.
    Toner, GC
    Mitchell, PL
    De Boer, R
    Gibbs, P
    Hicks, R
    Scott, AM
    McArthur, G
    Brega, N
    Massimini, G
    McCarthy, T
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6143S - 6143S
  • [7] Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from phase II trials
    Motzer, R.
    Rini, B.
    Michaelson, M.
    Redman, B.
    Hudes, G.
    Wilding, I.
    Bukowski, R.
    George, D.
    Kim, S.
    Baum, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 227 - 227
  • [8] Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC)
    Rini, Brian I.
    George, Daniel J.
    Michaelson, M. Dror
    Rosenberg, Jonathan E.
    Bukowski, Ronald M.
    Sosman, Jeffrey A.
    Stadler, Walter M.
    Margolin, Kim
    Hutson, Thomas E.
    Baum, Charles M.
    ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [9] A phase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors
    Rosen, Lee S.
    Bello, Carlo L.
    Mulay, Marilyn
    Dinolfo, Melissa
    Baum, Charles
    CANCER RESEARCH, 2006, 66 (08)
  • [10] A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC).
    Ronnen, E. A.
    Kondagunta, G. V.
    Lau, C.
    Fischer, P.
    Ginsberg, M. S.
    Baum, M.
    Kim, S. T.
    Chen, I.
    Baum, C. M.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 225S - 225S
12345